Stronger Results, Buybacks and Activist Pressure Might Change The Case For Investing In H.B. Fuller (FUL)
H.B. Fuller (FUL) recently reported stronger Q2 and year-to-date results, including increased sales and a completed $134.32 million share repurchase program. The company is also facing pressure from activist investor Ancora Holdings Group regarding governance and performance. These factors collectively impact H.B. Fuller's investment outlook, emphasizing the importance of improved profitability, capital allocation decisions, and addressing activist concerns while managing existing debt levels.
H.B. Fuller (FUL) Could Be 21% Below Fair Value On Strong Results And Activist Pressure
H.B. Fuller (FUL) is currently under attention due to better-than-expected second-quarter results and recent activist pressure from Ancora Holdings Group regarding governance. Despite a recent dip in share price performance, the stock is estimated to be 20.8% undervalued with a fair value of $73.29, driven by factors like the acquisition of ND Industries and share repurchases. However, potential risks include weak demand and solar headwinds.
H.B. Fuller (FUL) Could Be 21% Below Fair Value On Strong Results And Activist Pressure
H.B. Fuller (FUL) is attracting attention due to stronger Q2 and H1 results and interest from activist investor Ancora Holdings Group. Despite recent share price cooling, Simply Wall St's narrative suggests FUL is 20.8% undervalued with a fair value of $73.29, driven by strategic acquisitions, restructuring benefits, and share repurchases. Investors are advised to review the company's underlying numbers, risks, and rewards to assess its true potential.
Price to earnings forward of H.B. Fuller Company – MUN:HB1
This article provides a brief snapshot of the "Price to earnings forward" for H.B. Fuller Company (MUN:HB1) on the TradingView platform. It indicates that the market is closed and no trades have occurred for this specific financial metric. The content primarily consists of navigation links and disclaimers from TradingView and its data providers.
Louisiana State Employees Retirement System Takes $1.49 Million Position in H. B. Fuller Company $FUL
The Louisiana State Employees Retirement System has initiated a new position in H. B. Fuller Company, acquiring 24,100 shares valued at approximately $1.49 million during the first quarter. This move is part of a broader trend of institutional interest, with such investors now owning 95.93% of the company's shares. H. B. Fuller has also reported strong quarterly earnings, beating analyst expectations, and has an average "Moderate Buy" rating from analysts with a price target of $67.86.
FUL - H.B. Fuller Company Options
This article provides a detailed financial overview of H.B. Fuller Company (FUL). It includes key financial metrics such as market capitalization, income, sales, dividend information, and various price ratios. The report also covers insider and institutional ownership, profitability, stock performance, and analyst recommendations.
H.B. Fuller (FUL) Stock Looks Cheap On Cash Flow But Fair On Earnings
H.B. Fuller (FUL) stock appears undervalued based on a Discounted Cash Flow (DCF) analysis, which suggests it trades about 38.4% below its intrinsic value, driven by optimistic cash flow expectations from an upcoming acquisition. However, its P/E ratio of 16.6x indicates it is fairly valued compared to its industry and fair P/E estimate. The valuation debate centers on whether the market price adequately accounts for the risks and potential benefits of the Advanced Medical Solutions acquisition.
H. B. Fuller Company $FUL Holdings Cut by Deprince Race & Zollo Inc.
Deprince Race & Zollo Inc. significantly reduced its stake in H. B. Fuller Company ($FUL) by 5.6% during the first quarter of 2026, selling 43,512 shares and retaining 727,546 shares valued at approximately $44.9 million. This adjustment in institutional holdings comes as H. B. Fuller reported strong quarterly earnings, beating estimates with $1.41 EPS and achieving a 5.8% year-over-year revenue increase to $950.27 million. The specialty chemicals company also increased its quarterly dividend to $0.245 per share, and analysts maintain a "Moderate Buy" consensus rating with a target price of $67.86.
H.B. Fuller Q2 Earnings Call Flags Pricing, AMS Ambitions
H.B. Fuller's Q2 fiscal 2026 earnings beat estimates, driven by strong pricing actions and restructuring savings. The company raised its full-year profit outlook and highlighted the proposed acquisition of Advanced Medical Solutions as a key strategic move to expand into faster-growing medical end markets. While navigating mixed end-market conditions, management emphasized the durability of its pricing strategies and the long-term benefits of the AMS deal despite initial leverage concerns.
H.B. Fuller Bids on Advanced Medical Solutions
H.B. Fuller has made a recommended cash offer to acquire Advanced Medical Solutions Group, viewing medical as a core strategic growth market due to its robust demand, high regulatory barriers, and strong margin profile. This acquisition is expected to significantly increase H.B. Fuller's market presence, expand its capabilities in medical adhesives, and generate substantial revenue and cost synergies, ultimately transforming it into a higher-growth, higher-margin business. The deal combines AMS's differentiated surgical adhesive technologies and global commercial footprint with H.B. Fuller's existing infrastructure, aiming for considerable financial benefits and an expanded total addressable market.
H.B. Fuller Announces Recommended Cash Offer to Acquire Advanced Medical Solutions
H.B. Fuller plans to acquire Advanced Medical Solutions (AMS) through a recommended cash offer. This acquisition aims to expand H.B. Fuller's medical adhesives portfolio, strengthen its presence in healthcare, and increase its total addressable market by integrating AMS's innovative products and global operations. The merger is expected to drive significant revenue growth, operational efficiencies, and enhance the company's long-term financial performance.
Did Stronger Earnings and Completed Buybacks Just Shift H.B. Fuller’s (FUL) Investment Narrative?
H.B. Fuller recently reported stronger Q2 and six-month fiscal 2026 results, including higher sales and net income, along with the completion of a multi-year share repurchase program totaling US$89.49 million. This combination of improved earnings and share buybacks could influence the company's investment narrative, emphasizing earnings resilience and balance sheet flexibility. While the immediate picture remains margin-focused, investors should still consider potential risks from higher raw material costs and softer demand.
H. B. Fuller Company $FUL Shares Bought by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in H. B. Fuller Company (NYSE:FUL) by 62.6% in Q1, bringing its total holdings to 107,901 shares valued at approximately $6.7 million. This move comes as H. B. Fuller reported better-than-expected quarterly earnings and revenue, and raised its quarterly dividend. Analysts maintain a "Moderate Buy" rating with an average price target of $66.33, despite some mixed sentiment regarding a recent acquisition.
HB Fuller moves to acquire advanced medical solutions in strategic deal
H.B. Fuller, the world’s largest pure-play adhesives manufacturer, announced its intent to acquire Advanced Medical Solutions Group in an all-cash offer valued at £715 million. This strategic acquisition aims to significantly expand H.B. Fuller's presence in high-growth medical markets, including medical adhesives and biosurgical technologies, projecting an increase of $15 billion to its total addressable market. The deal, expected to close by year-end 2026, also anticipates £55 million in annual run-rate synergies by 2031 through cost savings and operational efficiencies.
Why H.B. Fuller Is Buying Advanced Medical Solutions For £715 Million
H.B. Fuller is acquiring Advanced Medical Solutions Group for £715 million, a move expected to significantly expand H.B. Fuller's capabilities in the high-growth medical market. The acquisition will introduce new surgical adhesive technologies, increase H.B. Fuller's total addressable market by $15 billion, and is projected to generate about $55 million in synergies by 2031. This strategic purchase aims to accelerate H.B. Fuller's long-term revenue growth and EBITDA margin targets, reinforcing its position as the world's largest pure-play adhesives company.
H. B. Fuller (NYSE:FUL) Upgraded to Strong-Buy at Wall Street Zen
H. B. Fuller (NYSE:FUL) has been upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen, reflecting a generally positive outlook from analysts. This comes after the specialty chemicals company reported strong Q2 earnings, with EPS and revenue both exceeding estimates. The article also highlights insider share acquisition and institutional investor activity, alongside recent news concerning an acquisition and future guidance.
H.B. Fuller Earnings Call: Growth, Cash and AMS Risk
H.B. Fuller's Q2 earnings call revealed solid performance with growth in revenue, margins, and EPS, along with record cash flow. However, this positive outlook is tempered by ongoing raw material inflation, supply-chain disruptions, and investor skepticism regarding the planned acquisition of Advanced Medical Solutions (AMS) due to an expected spike in leverage. The company provided updated full-year guidance, expressing confidence in earnings and cash generation despite volume pressures and the financial risks associated with the AMS deal.
Price to book forward of H.B. Fuller Company – SWB:HB1
This article provides financial information for H.B. Fuller Company (SWB:HB1), specifically focusing on its price-to-book forward ratio. It briefly displays the company's stock exchange listing on the Stuttgart Stock Exchange and indicates market status as closed with no trades. The content primarily lists various sections and features available on the TradingView platform related to market data, community interactions, and educational resources.
H.B. Fuller (NYSE: FUL) plans £715m AMS deal with $55m synergies
H.B. Fuller (NYSE: FUL) has announced a recommended cash offer to acquire UK-based Advanced Medical Solutions Group plc (AMS) for an enterprise value of £715 million, targeting high-growth medical markets. The deal is expected to generate approximately $55 million in combined run-rate revenue and cost synergies by 2031 and is being financed through secured and unsecured bridge credit facilities. H.B. Fuller plans to rapidly deleverage its net leverage to 2.5x to 3x within two years following the transaction's completion, which is anticipated by the end of 2026, subject to regulatory and shareholder approvals.
H.B. Fuller to Acquire Advanced Medical Solutions for 285p; Secures $3.0B Bridge Financing
H.B. Fuller announced its recommended cash acquisition of Advanced Medical Solutions for 285 pence per share, facilitated by a UK court-sanctioned scheme of arrangement. To fund this acquisition and manage liquidity, H.B. Fuller secured $3.0 billion in bridge financing, comprising both secured and unsecured facilities led by Goldman Sachs Bank USA. The transaction, backed by AMS directors, is expected to close by year-end 2026, pending shareholder and regulatory approvals, to expand H.B. Fuller's medical adhesives footprint.
H.B. Fuller to Acquire AMS for $942M in Medtech Push
H.B. Fuller, the world's largest adhesives company, plans to acquire Advanced Medical Solutions Group for $942 million in cash, significantly expanding its presence in the medical technology market. This acquisition is expected to add $15 billion to H.B. Fuller's total addressable market, bringing it to $95 billion, by extending capabilities in tissue bonding, tapes, dressings, and biosurgicals. Despite strong financial performance and strategic alignment with high-growth medical vertical, the deal faces opposition from activist investor Ancora, who expressed concerns about shareholder value.
H.B. Fuller defies shareholder opposition, proceeding with $943M acquisition
H.B. Fuller is moving forward with its largest acquisition in years, a $943 million deal to buy U.K.-based Advanced Medical Solutions (AMS), despite public opposition from some shareholders like Ancora Holdings Group concerned about the company's debt. CEO Celeste Mastin stated that H.B. Fuller had been pursuing AMS for three years, and the deal is essential to expanding into higher-margin medical adhesives. The acquisition will significantly boost H.B. Fuller's medical division and is a rare opportunity to advance its portfolio, according to Mastin.
H.B. Fuller Sees $55M Synergy Potential From AMS Deal – But Investors Are Still Selling FUL Stock
H.B. Fuller announced its acquisition of UK-based Advanced Medical Solutions Group Plc for £715 million, anticipating $55 million in combined revenue and cost synergies by 2031, and an increase of $300 million in annual revenue. Despite these projected benefits and strong Q2 earnings that beat analyst expectations, FUL stock was down over 6% in premarket trading. The deal is expected to close by the end of the calendar year and will broaden H.B. Fuller’s product portfolio with a new medical adhesives segment, expanding its total addressable market to $95 billion.
H.B. Fuller (FUL) Stock Sees Margin Improvement That Tests Bearish Leverage Narrative
H.B. Fuller (FUL) reported improved Q2 2026 results, with increased revenue and EPS, and significantly higher net margins. While this supports a bullish narrative regarding operational efficiency and acquisitions, challenges remain in certain segments and concerning its debt levels. The article discusses how these results impact the ongoing debate between bullish and bearish investor sentiments regarding the company's long-term prospects, particularly around valuation, growth, and leverage.
Price to sales forward of H. B. Fuller Company – NYSE:FUL
This article provides the "Price to sales forward" metric for H. B. Fuller Company (NYSE: FUL). It indicates that the market was closed with no trades at the time of publication and gives a brief overview of where to find financial and other company-related data on the platform. The content is primarily a data point embedded within a larger financial information platform.
Enterprise value to EBIT forward of H.B. Fuller Company – SWB:HB1
This article displays the "Enterprise value to EBIT forward" metric for H.B. Fuller Company (SWB:HB1) on the TradingView platform. It shows the metric's period, value, and change, indicating it is an economic indicator. The page provides financial data and other information for the company on the Stuttgart Stock Exchange.
H. B. Fuller Company (NYSE:FUL) Given Consensus Rating of "Moderate Buy" by Analysts
H. B. Fuller Company (NYSE:FUL) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $66.40. The company recently reported strong Q2 results, surpassing revenue and EPS estimates, and raised its full-year EPS guidance. However, a planned £715 million acquisition of Advanced Medical Solutions has drawn criticism from an activist investor regarding capital allocation and execution risk.
In rebuff to Ancora, H.B. Fuller agrees to acquire U.K. medical products firm for $870M
H.B. Fuller has announced it will acquire a U.K. medical products firm for $870 million, a move seen as a rebuff to Ancora. The article highlights this acquisition within the business news context from Crain's Cleveland Business.
H.B. Fuller Company 2026 Q2 - Results - Earnings Call Presentation (NYSE:FUL) 2026-06-25
H.B. Fuller Company (NYSE:FUL) announced its Q2 2026 earnings results, with an EPS of $1.41, beating estimates by $0.03, and revenue of $950.27M, a 5.81% year-over-year increase, exceeding projections by $25.48M. The company published a slide deck in conjunction with its earnings call to report these financial outcomes.
H.B. Fuller Agrees to Acquire UK-Listed AMS for £659 Million
H.B. Fuller Co. has agreed to acquire Advanced Medical Solutions Group Plc, a UK-listed manufacturer of tissue-healing medical products, for £659 million ($870 million). The offer of £2.85 per share has been recommended by AMS's board and represents a 35% premium to the stock's closing price in May before acquisition talks became public. Including debt, the deal values AMS at £715 million.
Adhesives Giant H.B. Fuller Pushes Into Surgical Devices With £715m AMS Buy
H.B. Fuller has acquired AMS for £715 million, marking a strategic entry into the surgical devices market. The acquisition is intended to leverage regulatory barriers to entry and favorable demand and margin characteristics within the medical sector. This move aligns with H.B. Fuller's broader strategy to expand its presence in medical markets.
Advanced Medical Solutions mulls £715m HB Fuller takeover bid
HB Fuller has proposed a £715m ($942.5m) takeover of Advanced Medical Solutions (AMS), aiming to expand its presence in the medical sector, particularly wound care. The acquisition would broaden HB Fuller's product offerings to include formulated biosurgicals and tissue bonding adhesives, tapes, and dressings, while also leveraging AMS's European market reach and regulatory expertise. This deal is expected to add $300m in annual revenues for HB Fuller and has been unanimously recommended by AMS's board to its shareholders.
H.B. Fuller Stock Slips After Bold Acquisition Bet
H.B. Fuller (FUL) stock declined after the company announced a fully financed, all-cash offer of £715 million for U.K.-based Advanced Medical Solutions. Despite reporting strong Q2 results and projecting mid-single-digit revenue growth, the acquisition raised investor concerns about significant execution risk and potential strain on the company's already leveraged balance sheet. The deal could limit H.B. Fuller's financial flexibility, making it harder to manage future downturns or pursue growth and shareholder returns.
Is H.B. Fuller (FUL) Below Fair Value Or Is Its Growth Already Priced In?
H.B. Fuller (FUL) recently closed at US$64.60, showing mixed share price movements. While a narrative based on earnings and strategic acquisitions suggests a modest undervaluation with a fair value of $70.43, a Discounted Cash Flow model indicates the stock might be overvalued at its current price, pointing to a future cash flow value of approximately $60.01. Investors are encouraged to review both perspectives, considering potential risks like raw material costs and solar segment weakness, to make an informed decision.
Advanced Medical Solutions soars 16% as H.B. Fuller seals £715 million takeover
U.S. adhesives manufacturer H.B. Fuller has agreed to acquire British medical supplier Advanced Medical Solutions for approximately £715 million in a cash deal. The acquisition, which offers a 35% premium per share, is expected to generate $55 million in annual run-rate synergies by 2031 and broaden H.B. Fuller's medical adhesives portfolio. This takeover highlights a trend of overseas buyers targeting undervalued U.K.-listed companies.
H.B. Fuller Nears £628 Million Deal for UK Medtech AMS
H.B. Fuller Co. is reportedly nearing an agreement to acquire Advanced Medical Solutions Group Plc, a UK-based maker of tissue-healing medical products. The deal is valued at £628 million ($827 million) and would see the US adhesives manufacturer offering £2.85 per share for AMS. This acquisition would mark H.B. Fuller's expansion into the healthcare sector and represents a 35% premium to AMS's stock close in May before deal discussions became public.
H.B. Fuller Announces Offer to Acquire Advanced Medical Solutions
H.B. Fuller has announced a recommended cash offer to acquire Advanced Medical Solutions Group plc for £715 million. This acquisition is expected to expand H.B. Fuller's capabilities in the medical segment, accelerate its path to higher growth and margins, and deliver approximately $55 million in run-rate synergies by 2031. The deal aims to enhance their portfolio with differentiated surgical adhesive technologies and expand their total addressable market.
H.B. Fuller beats Q2 estimates; raises full-year midpoint outlook
H.B. Fuller (FUL) reported better-than-expected Q2 earnings and subsequently increased its full-year midpoint outlook. The company's performance indicates a strong financial quarter, leading to a positive revision of its future projections.
H. B. Fuller: Fiscal Q2 Earnings Snapshot
The article provides a fiscal Q2 earnings snapshot for H. B. Fuller. No specific financial details are available in the provided content, but it indicates a quarterly earnings report was made.
Earnings Flash (FUL) H.B. Fuller Company Reports Q2 Revenue $950.3M, vs. FactSet Est of $924.8M
H.B. Fuller Company (FUL) reported its Q2 revenue of $950.3 million, surpassing FactSet's estimate of $924.8 million. The company's fiscal Q2 adjusted earnings and revenue both increased. Additionally, H.B. Fuller now anticipates a fiscal 2026 adjusted EPS range of $4.60-$4.90, compared to FactSet's estimate of $4.84.
Upcoming Earnings Reports: H.B. Fuller Company (FUL) and More
H.B. Fuller Company (FUL) is scheduled to release its earnings report, an event keenly watched by investors for insights into its financial health and operational performance. The company, a key player in the adhesives and sealants market, boasts a GF Score of 80/100, indicating good potential for long-term returns, and its insider trading activity shows recent buying confidence. Investors will be evaluating the report for growth and profitability indicators, especially considering the current economic landscape.
H.B. Fuller (NYSE: FUL) executive receives new phantom stock award
H.B. Fuller's Senior VP of International Growth, Heather Campe, received a grant of 34.64 Phantom Units, valued at $64.31 each, bringing her total Phantom Units to 5,738.39. This transaction on June 22, 2026, primarily updates her holdings and is categorized as routine equity compensation, not open-market buying or selling. She also holds significant common stock, restricted stock units, and stock options with various exercise prices and expiration dates.
FULLER H B CO (NYSE: FUL) CFO adds Phantom Units in equity update
FULLER H B CO's Executive VP and CFO, John J. Corkrean, reported an equity update showing a grant of 195.98 Phantom Units, increasing his total to 34,423.73 units. These Phantom Units convert to common stock on a one-for-one basis. The filing indicates no open-market purchases or sales, but rather a compensation-related acquisition that adds to his existing common stock, restricted stock units, and employee stock options.
H.B. Fuller (FUL) Gets Higher Price Target from UBS on Earnings Optimism
UBS raised its price target for H.B. Fuller (FUL) to $71 from $63, while reiterating a Neutral rating, projecting a strong earnings quarter. JPMorgan also upgraded FUL to Neutral, citing valuation, though both firms noted the potential Advanced Medical Solutions deal as a factor influencing future share performance. H.B. Fuller is recognized as a Dividend King with a 5-Year Average Dividend Growth Rate of 7.72%.
H.B. Fuller (FUL) Q2 2026 Preview: EPS Est. $1.38, Reports June 25
H.B. Fuller Company (NYSE:FUL) is set to report its Q2 fiscal 2026 results on June 25, with analysts projecting an EPS of $1.38 on revenue of $924.8M. This forecast represents a significant 17% increase in earnings and a 3.0% growth in revenue year-over-year, indicating an expected margin expansion. Investor focus will be on the drivers of this profitability growth, including operational efficiency, raw material costs, and management's guidance for future performance.
Is Sustainability Expansion And Medical Adhesives M&A Altering The Investment Case For H.B. Fuller (FUL)?
H.B. Fuller (FUL) recently released its 2025 Sustainability Report, announcing initiatives in recyclable packaging, an aerospace center, and a proposed acquisition of Advanced Medical Solutions Group. These strategic moves, combined with analysts' higher growth expectations for Engineering Adhesives, suggest a focus on long-term environmental goals and portfolio expansion into high-value markets. The company's future investment narrative will depend on its ability to translate these growth initiatives into stronger cash generation while managing its elevated net debt to EBITDA.
Earnings Preview: H.B. Fuller to Report Financial Results Post-market on June 24
H.B. Fuller (NYSE: FUL) is scheduled to announce its Q2 2024 earnings after the market closes on Monday, June 24, 2024. Analysts predict the company will report earnings of $1.09 per share on revenue of $907.7 million. Investors will be closely watching for actual results compared to these expectations.
H.B. Fuller (FUL) Stock Could Be 8% Undervalued After Its 2025 Sustainability Report
H.B. Fuller (FUL) recently released its 2025 Sustainability Report, outlining 2030 goals for emissions, water, and waste. The stock has shown recent momentum, returning 11.27% over 30 days and 28.74% over 90 days, and analysts suggest it could be 8% undervalued compared to fair value estimates around $70. However, a P/E analysis presents a less favorable view, indicating mixed signals for investors.
Top Wall Street Forecasters Revamp H.B. Fuller Expectations Ahead Of Q2 Earnings
H.B. Fuller (NYSE: FUL) is set to release its Q2 earnings on June 24, with analysts expecting an increase in earnings per share to $1.38 and revenue of $923.62 million. The company recently raised its quarterly dividend by 4.3%. Several Wall Street analysts have updated their ratings and price targets for FUL, with most holding a positive outlook.
AMS Says H.B. Fuller Must Announce Firm Intention To Make Offer For Co By 2 July 2026
AMS (Advanced Medical Solutions) has announced that H.B. Fuller must declare a firm intention to make an offer for the company by July 2, 2026. This notice sets a deadline for H.B. Fuller regarding a potential acquisition bid, indicating significant corporate activity involving these two entities. The news is brief and directly states the imposed deadline for the offer.
